• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人抗-Rh(D)单克隆抗体H2D5D2F5轻链的部分氨基酸序列

Partial amino acid sequence of the light chain of human anti-Rh(D) monoclonal antibody H2D5D2F5.

作者信息

Dlouha A, Lecroisey A, Henschen A, Ruttyn Y, Rouger P, Keil B

机构信息

Unité de Chimie des Proteines, Institut Pasteur, Paris, France.

出版信息

Protein Seq Data Anal. 1991 Dec;4(6):319-24.

PMID:1812484
Abstract

Antibody H2D5D2F5 is a human monoclonal anti-Rh(D) IgG1 (lambda) produced by Epstein-Barr virus-immortalized B lymphocytes from a healthy donor. The complete amino acid sequence of the light (L) chain, with the exception of positions 94-97, was determined by Edman degradation of the intact chain, containing 30 residues, and derived tryptic and thermolytic peptides. Sequences of the peptides were aligned by comparison with the sequences of previously reported L chains. H2D5D2F5 L chain belongs to the first variable subgroup of human chains. Its sequence does not reveal striking differences when compared to those of other human lambda chains issued from myeloma or hybridoma.

摘要

抗体H2D5D2F5是一种人源单克隆抗Rh(D) IgG1(λ型),由来自健康供体的爱泼斯坦-巴尔病毒永生化B淋巴细胞产生。轻链(L链)完整序列(除94 - 97位外)通过对包含30个残基完整链以及衍生的胰蛋白酶和嗜热菌蛋白酶肽段进行埃德曼降解来确定。通过与先前报道的L链序列比较对肽段序列进行比对。H2D5D2F5 L链属于人源链的第一个可变亚组。与骨髓瘤或杂交瘤来源的其他人源λ链相比,其序列未显示出显著差异。

相似文献

1
Partial amino acid sequence of the light chain of human anti-Rh(D) monoclonal antibody H2D5D2F5.人抗-Rh(D)单克隆抗体H2D5D2F5轻链的部分氨基酸序列
Protein Seq Data Anal. 1991 Dec;4(6):319-24.
2
Subgroup assignment of a human monoclonal anti-Rh(D) antibody.一种人源单克隆抗Rh(D)抗体的亚组分配
Protein Seq Data Anal. 1991 Dec;4(6):317-8.
3
[Three-dimensional structure determination of antibodies. Primary structure of crystallized monoclonal immunoglobulin IgG1 KOL, I].[抗体的三维结构测定。结晶单克隆免疫球蛋白IgG1 KOL的一级结构,I]
Hoppe Seylers Z Physiol Chem. 1983 Jun;364(6):713-47.
4
Peptide mapping characterization by capillary electrophoresis of a human monoclonal anti-Rh(D) antibody produced for clinical study.用于临床研究的人源抗Rh(D)单克隆抗体的毛细管电泳肽图谱表征
J Capillary Electrophor. 1995 Jul-Aug;2(4):197-202.
5
[Rule of antibody structure. Primary structure of a human monoclonal IgAl-immunoglobulin (myeloma protein Tro). VI. Amino acid sequence of the L-chain, lambda-type, subgroup II].[抗体结构规则。人单克隆IgA1免疫球蛋白(骨髓瘤蛋白Tro)的一级结构。VI。λ型II亚组L链的氨基酸序列]
Hoppe Seylers Z Physiol Chem. 1979 Dec;360(12):1903-18.
6
[The rule of antibody structure. The primary structure of a monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The chymotryptic peptides of the H-chain, alignment of the tryptic peptides and discussion of the complete structure].[抗体结构规则。单克隆IgG1免疫球蛋白(骨髓瘤蛋白Nie)的一级结构。III. 重链的胰凝乳蛋白酶肽段、胰蛋白酶肽段的比对及完整结构的讨论]
Hoppe Seylers Z Physiol Chem. 1976 Nov;357(11):1571-604.
7
Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents.重组聚合IgG抗Rh:开发直接凝集试剂的新策略。
J Immunol Methods. 2009 Jan 1;340(1):1-10. doi: 10.1016/j.jim.2008.09.011. Epub 2008 Oct 9.
8
Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.通过液相色谱与质谱联用对在CHO和NS0细胞中产生的单克隆抗IGF-1受体抗体进行表征。
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):203-18. doi: 10.1016/j.jchromb.2004.06.052.
9
[The primary structure of crystallizable monoclonal immunoglobulin IgG1 Kol. II. Amino acid sequence of the L-chain, gamma-type, subgroup I].
Biol Chem Hoppe Seyler. 1989 Mar;370(3):263-72.
10
[The primary structure of a monoclonal IgA-immunoglobulin (IgA Tro), I: The amino acid sequence of the L-chain of lambda-type, subgroup II (author's transl)].[一种单克隆IgA免疫球蛋白(IgA Tro)的一级结构,I:λ型II亚组L链的氨基酸序列(作者译)]
Hoppe Seylers Z Physiol Chem. 1975 Aug;356(8):1333-5.